

Contents Volume 24, 1990

Volume 24, Number 1

1990

CONTENTS

Rx-to-OTC Switch

R. William Soller	1	Introduction
William E. Cooley	3	Overview by the Moderator
Robert G. Pinco	5	A Legal Perspective on Regulatory Approaches to Switch
Jerome A. Halperin	13	Strategic Issues in the Rx-to-OTC Switch
William E. Cooley	19	Discussion Panel
Paula Botstein	29	Criteria for Switching New Molecular Entities from Prescription to Over-the-Counter
William E. Gilbertson	33	Criteria For GRAS and GRAE Status for Switch Via the Monograph
Henry A. Palmer	41	OTC Information: Labeling Demands and Beyond
William E. Cooley	45	Question and Answer Session
Jonathan C. Peck	49	Future Health Care Trends Affecting Rx-to-OTC Switch
Stephen W. Schondelmeyer	57	Economic Aspects of Switch
William E. Cooley	67	Question and Answer Session
R. William Soller	73	Welcome and Introduction
Mark Novitch	75	Overview of the Health Professional Panel on Switch
Thomas Q. Garvey III	77	Switch Candidates from the GI Perspective
Leslie Hendeles	83	Switch Candidates from the Pulmonary Perspective

Howard I. Maibach	91	Switch Candidates from the Dermatological Perspective
Norman W. Lavy	95	Switch Candidates from the Internal Medicine Perspective
Mark Novitch	99	Health Professional Panel
Arthur Hull Hayes Jr	111	Overview of the Proceedings: The Future of Switch
Additional Articles		
A. C. Cartwright	115	Stereochemistry and Safety, Efficacy and Quality Issues: Genesis of New Regulations
Jeffrey R. Brown	117	Stereochemical Principles
Andrew K. Scott	121	Stereoisomers in Clinical Pharmacology
Charles S. Kumkumian	125	Regulatory Considerations Concerning Stereoisomers in Drug Products
Roger A. Sheldon	129	The Industrial Synthesis of Pure Enantiomers
Akira Kawahara	141	Regulatory Aspects of Biotechnology in Japan
Akira Kawahara	153	Present and Future Aspects of the Japanese Pharmaceutical Affairs Administration
R. Graham Hughes	169	The Management of Third-Party Trials in Europe
Theresa E. Stokes	177	Clinical Data Management – Technology Trends Survey
Vincente Anido Jr Ashok K. Gumbhir Suzan N. Kucukarslan	189	Comparison of Missouri and Kansas Community Pharmacists' Communication Performance
Georges Lagier René Jean Royer	203	Information to the Physician: Role of French Regional Pharmacovigilance Centres
Kenneth I. Kaitin	207	Impact of Policy Research on Drug Development Strategies
Ralph D. Harkins Renata Albrecht	213	Design and Analysis of Clinical Trials for Anti-Infective Drug Products
Thomas R. Beam Jr David N. Gilbert Calvin M. Kunin	225	Updated Guidelines for the Evaluation of New Anti-Infective Drug Products

Louis Lasagna 231 On Achieving Consensus Regarding Flexible Therapeutic End Points

Robert P. Baker 235 User Survey of an Industry-Based Drug Information Service

Thomas H. Perez 245 Adverse Reaction Reporting Requirements: An Update for Manufacturers

Paul L. Gittelson 251 A Quality Assurance Program for Sponsored Clinical Trials

Karl E. Peace 257 TMO: The Trial Management Organization—A New System for Reducing the Time for Clinical Trials

I Software Survey Section:
PC! info: Time-Oriented Data Management/Analysis System
Parnassa Regulatory Affairs Document Manager

Volume 24, Number 2

1990

CONTENTS

**Statistical Issues in Pharmaceutical Industry:
Experimental Design Considerations in Drug Development**

John R. Schultz 265 Introduction

David Salsburg 267 Mathematical Modeling and the Design of Studies in Drug Research

Carl M. Metzler 281 Medical and Statistical Design Issues in Clinical Pharmacology
James T. VanderLugt

Lianng Yuh 289 Latin Square Designs in a Comparative Bioavailability Study
Stephen J. Ruberg

H. J. Rostami 299 Experimental Design for Pharmacokinetics Modeling

Donald J. Schuirmann 315 Design of Bioavailability/Bioequivalence Studies

Jonathan B. Skinner 325 Early Exploration of Safety and Efficacy

Nancy L. Geller 341 Design of Phase I and II Trials in Cancer

Walter H. Carter, Jr Bruce E. Dornseif	351	Maximizing Drug Benefit in Combination Therapy (Dose-Response Estimation)
Mary F. Johnson	361	Issues in Planning Interim Analyses
H. M. James Hung Tie-Hua Ng George Y. H. Chi Raymond J. Lipicky	371	Response Surface and Factorial Designs for Combination Antihypertensive Drugs
Lilly P. Sanathanan	379	Introduction: Statistical Issues in Animal Safety Studies
Daniel Krewski Michael Goddard	381	Principles of Bioassay Design
Patrick J. Wier John R. Ventre	395	Statistical Analyses of Reproductive and Developmental Toxicology Studies
Gary G. Koch Sandra Stinnett William A. Sollecito	407	Summary and Discussion for Experimental Design Considerations in Drug Development
Additional Articles		
Gerald A. Faich Winifred Castle Zbigniew Bankowski The CIOMS ADR Working Group	419	International Adverse Drug Reaction Reporting: The CIOMS Project
Jan Rosier Paul Demoen	427	Requirements for Chemical and Pharmaceutical Data in Support of Clinical Trial Applications in the United Kingdom, Canada, the USA, the Nordic Countries, and Australia
	449	Letter to the Editor

I Software Survey Section

CONTENTS

Michael R. Hamrell	451	FDA Perspective on Computer Assisted Pharmacology/Toxicology Review
---------------------------	-----	------------------------------------------------------------------------

Rodney Charles Hall 457 **Collaboration Between Australia and Sweden in Drug Regulation**
Paul Isaacson
Per Sjoberg
Ture Sjoblom
Kjell Strandberg
Olof Tyden

Bette Lee Barton 463 **FDA's Inspections of US and Non-US Clinical Studies**

Stephen G. Bryant 469 **Postmarketing Surveillance: Effects of Compensation on Patient Self-Monitoring**
Seymour Fisher
David B. Larson
Nancy J. Olins

Brian L. Strom 477 **Medicaid Billing Data Used to Study the Effects of Marketed Drugs**
Jeffrey L. Carson

Uli Hacksell 485 **Stereoselectivity of Drug Receptor Interactions**
Lars-Erik Arvidsson
Anette M. Johansson
Anders Karlén
Kristina Luthman
Stephan Hjorth

Robert E. Pearson 497 **Contribution of Computerized Content Analysis to Visualization of *USP DI***
Bill G. Felkey
J. Tyrone Gibson
Kenneth N. Barker

Raymond W. Falk 507 **Basic Guidelines for Inference From Clinical Trial Data**

Charlotte A. Jankel 513 **The Effectiveness of Computerized Drug Interaction Screening Programs in Hospitals**
John A. McMillan
Stuart M. Speedie

William E. Cwiklo 531 **Standards for CANDAs; Do CALS Standards Point the Way?**
B. Tommie Usdin

Nancy E. Nazari 537 **ICI's Patient Assistance Program**
Yvonne Graham

Gregory G. Enas 541 **Baseline Comparability in Clinical Trials: Prevention of "Poststudy Anxiety"**
Nathan H. Enas
C. Thomas Spradlin
Michael G. Wilson
Curtis G. Wiltse

L. S. Kaufman 549 **Clinical Study Authorizations: Development Strategies**
C. S. Snoddy, Jr

Phn Nelly Baudrihaye	561	Events and Milestones on the Road to 1992—The Needs of Industry in View of the Internal Market and Evolving Regulatory Procedures
Bjørn Jøldal	569	EFTA/EEC: A Review of Progress in the Harmonization of Regulatory Requirements; Collaboration and Interaction Between Authorities; the PIC and the PER Scheme
Martha M. Meinzinger William S. Barry	575	Prospective Study of the Influence of the Media on Reporting Medical Events
Paul Mensinga Danielle Gabarra	579	Clinical Quality Assurance: A Method for the Quantification of In-House Audits
Jan Rosier Paul Demoen	583	Labeling of Clinical Trial Samples: An Overview of Some Regulatory Requirements
Robert H. Denlinger	591	Industry Perspective on Computer Assisted Toxicology/Pharmacology Review
J. Greg Perkins Michael Dalton George M. Lyon	597	Utility of Retrovir's® Phase IV Research From a Regulatory Perspective
Charles F. Curran Osman Bawa	605	Implementation of a Worldwide Drug Safety Surveillance System
Peter P. Lamy	615	Patient Package Inserts: The Voluntary Approach
Harry Irving Katz Sheila L. Katz Lionel D. Edwards John J. Mooney	621	Survey Results of Remote Data Entry Use by Clinical Investigator Sites
Lionel D. Edwards	629	Multinational Experience Using Remote Data Entry in Clinical Studies
S. Mela	635	European Communities: Outstanding White Paper Proposals for the Completion of Internal Market in the Pharmaceutical Sector
Louis A. Morris David B. Banks	639	New Issues in Drug Advertising and Labeling: The Five Advertising End-Runs
I		Software Survey Section: <i>Scratchcard Analysis</i> <i>BioGraf</i> <i>IRB info: Institutional Review Board Data Management System</i> <i>Entrypoint 90</i>

Volume 24, Number 4

1990

CONTENTS

Preclinical Computer and Statistical Applications

Karl E. Peace 647 Introduction

Seth Michelson 649 **PEAS—A Parameter Estimation Analysis System: An In-Laboratory Analysis Tool**
Mark Bradshaw

Chuck Villarrubia

Bruce Ingraham

Eric M. Chi 659 Analysis of Longitudinal Data by Models with Random Effects and AR(1) Errors

C. Thomas Lin 671 Applications of Partial Least Squares to Spectral Data for Quantitative Determinations of Chemicals in a Mixture

Peter C. Jurs 691 Clustering Tendency Applied to Chemical Feature Selection
Richard G. Lawson

James W. McFarland 705 Cluster Significance Analysis: A New QSAR Tool for Asymmetric Data Sets
Daniel J. Gans

Jia-Lin Syi 713 Investigation of the Dissociation Process of the Inhibitor Methotrexate from the Methotrexate-Lactobacillus Casei Dihydrofolate Reductase Complex by Using Molecular Dynamics and Semiempirical Molecular Orbital Methods
Rick Gussio
Jih-Hsiang Chen

Mirza W. Ali 727 Exact Versus Asymptotic Tests of Trend of Tumor Prevalence in Tumorigenicity Experiments: A Comparison of *P*-Values for Small Frequency of Tumors

Kem F. Phillips 739 The Statistical Analysis of Data from Bioequivalence Studies Using Stable Isotopes

Lianng Yuh 747 Robust Procedures in Comparative Bioavailability Studies

Shein-Chung Chow 753 Alternative Approaches for Assessing Bioequivalence Regarding Normality Assumptions

Additional Articles

Rona S. Wasserman 763 Use of an Electronic Publishing System for Production of Pharmaceutical Product Literature

Terry L. Gillum 769 Dictionary Design for Clinical Data Management

Elisabetta Ortelli 775 Present and Future of a Private Biomedical
Aldo Ferrario Database

Alan Gelberg 785 A Study of the Utilization of the FDA's Adverse
George D. Armstrong Drug Reaction Database

Frances O. Kelsey 795 FDA Perspective on IRBs and Overview of FDA
Inspection of IRBs

I Software Survey Section:
HASL v. 3.17

V Volume 24 Contents and Author Index

